UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

~~November~~February 123, ~~2024~~ 2025

COMMISSION FILE NUMBER 001-36285

Incorporated in the State of Delaware

I.R.S. Employer Identification Number 46-4559529

Rayonier Advanced Materials Inc.

1301 Riverplace Boulevard, Jacksonville, Florida 32207

(Principal Executive Office)

Telephone Number: (904) 357-4600

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Exchange on which Registered

Common Stock, $0.01 par value

RYAM

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 12.~~01.~~02 ~~Entry~~Results ~~Into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Condition

On ~~November 12~~February 3, ~~2024~~2025, ~~RYAM BioNova SAS, a French simplified joint-stock company (“RYAM BioNova SAS”), as Borrower, and~~ Rayonier ~~A.M. France SAS, a French simplified joint-stock company (“RYAM France”), as Guarantor, each subsidiaries of Rayonier~~ Advanced Materials Inc. ~~(“RYAM”)~~issued ~~entered into~~ a ~~Senior~~press ~~Credit~~release ~~Loan~~announcing ~~Agreement~~preliminary ~~for~~unaudited ~~€37~~financial ~~million~~results infor ~~secured term loans with Crédit Lyonnais, Arkéa Banque Entreprises et Institutionnels, and BNP Paribas (~~the ~~“Credit~~year ~~Agreement”). The~~ended ~~Credit Agreement establishes a credit facility of EUR 37~~December 31,~~000,000,~~ ~~divided into Tranche A, totaling EUR 27,750,000, and Tranche B, totaling EUR 9,250,000~~2024. ~~Borrowings under the facility bear interest at a floating rate tied to EURIBOR, with an initial margin of 2.00% per annum for Tranche~~ A ~~and~~copy 2.50% per annum for Tranche B, subject to adjustment based on certain financial performance metrics. Tranche A requires quarterly principal repayments commencing February 12, 2027, with each installment amounting to 5% of the ~~drawn~~press ~~amount,~~release ~~and~~is ~~the~~furnished ~~outstanding~~herewith ~~balance~~as toExhibit ~~be fully repaid by the final maturity date of November 12, 2031~~99. ~~Tranche~~1 Band is ~~structured~~incorporated ~~with~~by areference ~~single balloon repayment at its maturity date on November 12, 2032~~herein. ~~Drawdowns are available under the Credit Agreement until the second anniversary of the Credit Agreement, subject to customary conditions precedent.~~

OnThe ~~November~~information ~~12,~~in ~~2024,~~this ~~RYAM~~Item ~~France~~2.02, ~~RYAM,~~including ~~RYAM~~the ~~BioNova~~accompanying ~~SAS~~exhibit, ~~and~~is ~~SWEN~~furnished ~~Impact~~and ~~Fund~~shall ~~for~~not ~~Transition~~be 3deemed (“~~SWEN~~filed”) ~~entered~~for ~~into~~ the ~~RYAM BioNova~~purposes ~~Shareholder~~of ~~Agreement~~Section ~~(the~~18 ~~“Shareholder~~of ~~Agreement”)~~the inSecurities ~~connection~~Exchange ~~with~~Act ~~SWEN’s~~of ~~equity~~1934, ~~investment~~as inamended ~~RYAM~~(the ~~BioNova~~“Exchange ~~SAS~~Act”), ~~which contemplates~~and ~~that SWEN~~ will ~~fund~~not ~~up to €30 million in exchange for preferred shares representing a 20% ownership stake RYAM BioNova SAS. Of this commitment, €15 million is to~~ be ~~funded~~incorporated atby ~~closing,~~reference ~~with~~into ~~subsequent~~any ~~funding~~filing ofpursuant ~~the balance~~ to ~~be made contingent on achievement of key RYAM BioNova SAS project milestones. As~~ the ~~holder~~Securities ofAct ~~the preferred shares, SWEN is entitled to a minimum internal rate~~ of ~~return (IRR) of 16% and a 2x investment multiple. SWEN also holds a preferential right to dividends~~1933, ~~ensuring~~as ~~distributions are prioritized to meet these return objectives before ordinary shareholders~~amended, ~~and is~~or ~~entitled~~the toExchange ~~certain exit rights. A RYAM BioNova SAS supervisory committee~~Act, ~~consisting~~regardless of ~~three~~any ~~RYAM-appointed~~general ~~members~~incorporation ~~and~~language ~~one~~in ~~SWEN-appointed~~such ~~member, has been established to oversee RYAM BioNova SAS’s strategic direction~~filing.

~~The~~Item ~~above~~9.01 ~~summaries~~Financial ofStatements ~~the material terms of the Credit Agreement~~ and the Shareholder Agreement are not intended to be exhaustive and are qualified in their entirety by reference to the full text of each agreement, each of which will be included as exhibits to RYAM's 2024 Form 10-K.Exhibits

~~Item~~(d) ~~7.01. Regulation FD Disclosure~~Exhibits

RYAM issued a press release announcing the Credit Agreement and SWEN’s equity investment in RYAM BioNova SAS.


99.1			Rayonier Advanced Materials Announces Preliminary Full Year 2024 Results
104			Cover page interactive data file (embedded within the Inline XBRL document)

A copy of the press release announcing the debt and equity transactions is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

99.1	Press release entitled “RYAM Raises €67 million Green Capital to Invest in its Biomaterials Strategy”
104	Cover page interactive data file (embedded within the Inline XBRL document)

Signature

Pursuant to the requirements of the Securities Exchange Act of l934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Rayonier Advanced Materials Inc.
By:	~~/s/ R. COLBY SLAUGHTER~~	/s/ GABRIELA GARCIA
	R. Colby Slaughter
		Gabriela Garcia
	Senior Vice President, General Counsel and Corporate Secretary
		Chief Accounting Officer and Vice President, Corporate Controller
	Date: November 18, 2024
		Date: February 4, 2025

Filing Compare · RAYONIER ADVANCED MATERIALS INC.